Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic...
Wernicke, Alla G.; Kim, Sae; Liu, He; Bander, Neil H.; Pirog, Edyta C.
2017-04-01 00:00:00
The goal of the study was to examine expression of prostate-specific membrane antigen (PSMA) in neovasculature of gynecologic cancers, as PSMA-targeted therapy has showed a promise in treatment of advanced carcinomas. The study included cervical carcinoma (n=28), vulvar carcinoma (n=20), endometrial carcinoma (n=23), primary ovarian carcinoma (n=21), metastatic ovarian carcinoma (n=25), and normal cervix (n=12) as negative control. All cases were immunostained using anti-CD31 antibody to delineate capillary endothelial cells. In parallel, all cases were immunostained using anti-PSMA antibody. The PSMA staining was assessed in tumor capillaries and in normal tissues and scored as a percentage of CD31 staining. PSMA expression was found in the tumor neovasculature, and no significant expression was identified in vasculature of normal tissues. The extent of PSMA staining in tumor capillaries varied from high expression in ovarian and endometrial cancers, to medium expression in cervical squamous cell carcinomas, and low expression in cervical adenocarcinomas and vulvar cancers. All (100%) cases of primary ovarian carcinoma, ovarian carcinoma metastases, and primary endometrial carcinoma showed PSMA expression in tumor vasculature, which was diffuse in majority of cases. The expression of PSMA in ovarian cancer metastases was similar among different metastatic foci of the same tumor. Fifteen percent of cervical squamous cell carcinoma, 50% of cervical adenocarcinoma, and 75% of vulvar carcinomas showed no capillary expression of PSMA. In conclusion, PSMA is highly and specifically expressed in the neovasculature of ovarian, endometrial, and cervical squamous carcinoma, rendering it a potential therapeutic vascular target.
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngApplied Immunohistochemistry & Molecular MorphologyWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/prostate-specific-membrane-antigen-psma-expression-in-the-4HWyRyDCmz
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy
The goal of the study was to examine expression of prostate-specific membrane antigen (PSMA) in neovasculature of gynecologic cancers, as PSMA-targeted therapy has showed a promise in treatment of advanced carcinomas. The study included cervical carcinoma (n=28), vulvar carcinoma (n=20), endometrial carcinoma (n=23), primary ovarian carcinoma (n=21), metastatic ovarian carcinoma (n=25), and normal cervix (n=12) as negative control. All cases were immunostained using anti-CD31 antibody to delineate capillary endothelial cells. In parallel, all cases were immunostained using anti-PSMA antibody. The PSMA staining was assessed in tumor capillaries and in normal tissues and scored as a percentage of CD31 staining. PSMA expression was found in the tumor neovasculature, and no significant expression was identified in vasculature of normal tissues. The extent of PSMA staining in tumor capillaries varied from high expression in ovarian and endometrial cancers, to medium expression in cervical squamous cell carcinomas, and low expression in cervical adenocarcinomas and vulvar cancers. All (100%) cases of primary ovarian carcinoma, ovarian carcinoma metastases, and primary endometrial carcinoma showed PSMA expression in tumor vasculature, which was diffuse in majority of cases. The expression of PSMA in ovarian cancer metastases was similar among different metastatic foci of the same tumor. Fifteen percent of cervical squamous cell carcinoma, 50% of cervical adenocarcinoma, and 75% of vulvar carcinomas showed no capillary expression of PSMA. In conclusion, PSMA is highly and specifically expressed in the neovasculature of ovarian, endometrial, and cervical squamous carcinoma, rendering it a potential therapeutic vascular target.
Journal
Applied Immunohistochemistry & Molecular Morphology
– Wolters Kluwer Health
Published: Apr 1, 2017
Recommended Articles
Loading...
References
Angiogenesis
The role of angiogenesis in solid tumours: an overview
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Prostate-specific membrane antigen expression in normal and malignant human tissues
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
Prostate-specific membrane antigen is produced in tumor-associated neovasculature
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers
Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme
Chapter 16: cancers of the ovary
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
Expression of the prostate-specific membrane antigen
Prostate-specific membrane antigen expression in regeneration and repair
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate specific membrane antigen (PSMA)
Phase I trial results of 90Yttrium labeled anti-prostate specific membrane antigen monoclonal antibody J591 in the treatment of patients with recurrent prostate cancer
Phase I trial results of 177Lutetium-labeled j591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
Prostate-specific membrane antigen vaccines: naked DNA and protein approaches
Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?
A prospective pilot study of 89Zr-J591/PSMA positron emission tomography (PET) in men with localized prostate cancer undergoing radical prostatectomy
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
